Have we observed any changes in the epidemiology and management of chronic hepatitis B?
Authors:
J. Stránský 1; J. Kynčl 2
Authors‘ workplace:
I. interní klinika FNKV a 3. LF UK, Praha
Přednosta: prof. MUDr. Jiří Horák, CSc.
1; Státní zdravotní ústav Praha
Odbor epidemiologie infekčních nemocí
Vedoucí: MUDr. Jitka Částková, CSc.
2
Published in:
Prakt. Lék. 2009; 89(7): 357-360
Category:
Reviews
Overview
A review of recent developments in the epidemiology and therapy of chronic hepatitis B with nucleoside and nucleotide analogues and suitable recommendations for treatment.
Key words:
chronic hepatitis B, analogues therapy.
Sources
1. Ganem, D., Prince, A.M. Hepatitis B virus infection – natural history and clinical consequences. N. Engl. J. Med. 2004, 350, p. 1118-1129.
2. Lavanchy, D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J. Viral Hepat. 2004, 11, p. 97-107.
3. Marcellin, P., Dusheiko, G., Zoulim, F. et al. EASL Clinical Practise Guidelines: management of chronic hepatitis B. J. Hepatol. 2009, 50, p. 227-242.
4. Hadziyannis S.J., Vassilopoulos, D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001, 34, p. 617-624.
5. Funk, M.L., Rosenberg, D.M., Lok A.S. World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J. Viral Hepat. 2002, 9, p. 52-61.
6. Zarski, J.P., Marcellin, P., Leroy, V. et al. Characteristics of patients with chronic hepatitis B in France: predominant frequency of HBe antigen negative cases. J. Hepatol. 2006, 45, p. 355-360.
7. Locarnini, S., McMillan, J., Bartholomeusz, A. The hepatitis B virus and common mutants. Sem. Liv. Dis. 2003, 23, p. 5-20.
8. Hoofnagle, J.H., Shafritz, D.A., Popper, H. Chronic type B hepatitis and the „healthy“ HBsAg carrier state. Hepatology 1987, 7, p. 758-763.
9. Fattovich, G. Natural history and prognosis of hepatitis B. Sem. Liv. Dis. 2003, 23, p. 47-58.
10. Perillo, R. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease, Gastroenterology 2001, 120, p. 1009-1022.
11. Lok, A., Heathcote, J., Hoofnagle, J. Management of hepatitis B 2000: summary of a workshop. Gastroenterology 2001, 120, p. 1828-1853.
12. Martinot-Peignoux, M., Boyer, N., Colombat, M. et al. Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers. J. Hepatol. 2002, 36, p. 543-546.
13. Seo, Y., Yoon, S., Truong, B.X. et al. Serum hepatitis B virus DNA levels differentiating inactive carriers from patients with chronic hepatitis B. Eur. J. Gastroenterol. Hepatol. 2005, 17, p. 753-757.
14. Kumar, M., Sarin, S.K., Hissr, S. et al. Virologic and histologic festures of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT. Gastroenterology 2008, 134, p. 1376-1384.
15. Tsang, F.S.Y., Trinh, H., Garcia, R.T. et al. Significant prevalence of histologic disease in patients with chronic hepatitis B and mildly elevated serum alanine aminotransferase levels. Clin. Gastroenterol. Hepatol. 2008, 8, p. 569-574.
16. Tanaka, Y., Esumi, M., Shikata, T. Persistence of hepatitis B virus DNA after serological clearance of hepatitis B virus. Liver 1990, 10, p. 6-10.
17. Loriot, M., Marcellin, P., Talbodec, N. et al. Demostration of hepatitis B DNA by polymerase chain reaction in the serum after spontaneous or therapeutically induced HBeAg to anti-HBe or HBsAg to anti-HBs seroconversion in patients with chronic hepatitis B. Hepatology 1992, 15, p. 32-36.
18. Arase, Y., Ikeda, K., Suzuki, F. et al. Long term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B. Am. J. Med. 2006, 119, E9-E16.
19. Ahn, S.H., Park, Y.N., Park, J.Y. et al. Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. J. Hepatol. 2005, 42, p. 188-194.
20. Adachi, H., Kaneko, S., Matsushita, E., et al. Clearance of HBsAg in seven patients with chronic hepatitis B. Hepatology 1992, 16, p. 1334-1337.
21. Yuen, M.F., Yuan, H.J., Wong, D.K. et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut 2005, 54, p. 1610-1614.
22. Chen, C.J., Yang, H.I., Su, J. et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. J. Amer. Med. Assoc. 2006, 295, p. 65-73.
23. Yuen, M.F., Wong, D.K.H., Fung, J. et al. HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology 2008, 135, p. 1192-1199.
24. Hoofnagle, J.H., Doo, E., Liang, T. J. et al. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007, 45, p. 1056-1075.
25. Dienstag, J.L., Schiff, E.R., Wright, T.L. et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N. Engl. J. Med. 1999, 341, p. 1256-1263.
26. Liaw, Y.F., Sung, J.J.Y., Chow, W.C. et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 2004, 351, p. 1521-1531.
27. Liaw, Y.F., Leung, N., Guan, R. et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Internat. 2005, 25, p. 472-489.
28. Yuen, M.F., Seto, W.K., Chow, D.H. et al. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antiviral Therapy 2007, 12, p. 1295-1303.
29. Marcellin, P., Lau, G. K.K., Bonino, F. et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 2004, 351, p. 1206-1217.
30. Marcellin, P., Chang, T.T., Lim, S.G. et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N. Engl. J. Med. 2003, 348, p. 808-816.
31. Hadziyannis, S., Tassopoulos, N.C., Heatcote, E.J. et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N. Engl. J. Med. 2003, 348, p. 800-807.
32. Chang, T.T., Gish, R.G., de Man, R. et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 2006, 354, p. 1001-1010.
33. Lai, C.L., Shouval, D., Lok, A.S. et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 2006, 354, p. 1011-1020.
34. Lai, C. L., Gane, E., Liaw, Y. F. et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N. Engl. J. Med. 2007, 357, p. 2576-2588.
35. Marcellin, P., Heathcote, E.J., Buti, M. et al. Tenofovir disoproxil fumarate versus adefovir for chronic hepatitis B. N. Engl. J. Med. 2008, 359, p. 2442-2455.
36. Dienstag, J.L. Drug therapy: hepatitis B virus infection. N. Engl. J. Med. 2008, 359, p. 1486-1500.
37. Dusheiko, G. A pill a day, or two, for hepatitis B ? Lancet 1999, 353, 1032-1033.
Labels
General practitioner for children and adolescents General practitioner for adultsArticle was published in
General Practitioner
2009 Issue 7
- Definition and Classification of Chronic Kidney Disease According to KDIGO
- Doc. Jiří Kubeš: The major benefit of proton therapy lies in protecting healthy tissues
- Minimally Invasive Treatment of Pilonidal Sinus: Laser and Negative Pressure Therapy as a Gentle and Effective Modality
- Trazodone as an Effective Medicine in the Therapy of Depression and Insomnia
- Diagnosis of Cow Milk Protein Allergy − Current Methods and Their Diagnostic Value
Most read in this issue
- Regional migratory osteoporosis – a differential diagnostic problem
- Professional misconduct and errors in medical practice
- Treatment of cannabis dependence
- Prevention of arterial thrombosis (arteriothromboprophylaxis) in clinical practice